Lab Head Screening and Assay Automation High Throughput Biologics, R&D Biologics Research/Protein Therapeutics, Sanofi-Aventis, Germany
The identification of multi-specific antibody molecules with favorable drug-like properties is more successful when a larger number of variants are tested. In this presentation, we introduce a novel automated platform process that enables the rapid generation of large panels of multi-specific antibody variants, with the capacity to produce and test up to 10,000 molecules. The robotic platform was designed and produced by Lab Services BV.
